
Teva Pharmaceuticals shares phase 3 data for Ajovy as migraine treatment
Betsy Goodfellow | December 6, 2023 | News story | Research and Development | Neurology, Teva Pharmaceuticals, ajovy, obesity
Teva Pharmaceuticals has announced data from a post hoc analysis of two phase 3 clinical studies around the effectiveness of migraine prevention treatment, Ajovy (fremanezumab) in the reduction of migraine attacks in patients with migraine and co-morbid obesity.
The analysis of the HALO-LTS and FOCUS phase 3 studies compared the safety and efficacy of the drug in obese migraine patients to normal weight migraine patients for six months. It was demonstrated that the efficacy of Ajovy remained consistent between BMI-high and BMI-normal patients.
Ajovy is a humanised monoclonal antibody (mAB) which selectively targets the calcitonin gene-related peptide (CGRP) approved for the prevention of migraine in adults who have at least four migraine days per month.
Dr Pablo Irimia Sieria, lead study author and consultant neurologist of the Clinica Universidad de Navarra, Pamplona, Spain, commented: “This analysis is encouraging as it shows fremanezumab can reduce migraine attacks as effectively in obese patients as it does in patients of normal weight. Considering the higher burden of migraine in patients with co-morbid obesity, it is important for treatments to demonstrate efficacy and safety in migraine patients with this particular comorbidity.”
Betsy Goodfellow
Related Content

FDA approves Wegovy for treatment of MASH in adults with liver fibrosis
The US Food and Drug Administration (FDA) has granted accelerated approval for Wegovy (semaglutide) as …

Lilly reports positive results from trial of obesity candidate
Eli Lilly and Company (Lilly) has announced topline results from its phase 3 ATTAIN-1 trial, …

MetP Pharma releases positive data on intranasal semaglutide administration
MetP Pharma has released new data highlighting the advantages of its MetP technology in delivering …






